Crystalline form of sitagliptin
    1.
    发明申请
    Crystalline form of sitagliptin 审中-公开
    西他列汀的结晶形式

    公开(公告)号:US20090221595A1

    公开(公告)日:2009-09-03

    申请号:US12313975

    申请日:2008-11-25

    CPC classification number: C07D487/04

    Abstract: A Sitagliptin crystalline form characterized by PXRD pattern having any 5 peaks selected from the group consisting of 7.4, 11.5, 16.7, 17.7, 18.9, 24.1, 24.5, 27.0, 28.5 and 28.8±0.2 degrees 2-theta, wherein any combination of peaks selected includes the peak at 7.4±0.2 degrees two theta, processes for preparing said Sitagliptin crystalline form, and pharmaceutical compositions thereof, are provided.

    Abstract translation: 西他列汀结晶形式,其特征在于具有选自7.4,11.5,16.7,17.7,18.9,24.1,24.5,27.0,28.5和28.8±0.2度2-θ的任何5个峰的PXRD图,其中所选择的峰的任意组合 包括峰值在7.4±0.2度2θ,制备所述西格列汀结晶形式的方法及其药物组合物。

    CRYSTALLINE FORMS OF SITAGLIPTIN PHOSPHATE
    6.
    发明申请
    CRYSTALLINE FORMS OF SITAGLIPTIN PHOSPHATE 审中-公开
    磷酸西他汀的结晶形式

    公开(公告)号:US20100041885A1

    公开(公告)日:2010-02-18

    申请号:US12410738

    申请日:2009-03-25

    CPC classification number: C07D487/04

    Abstract: A Sitagliptin phosphate characterized by data selected from the group consisting of: a powder XRD pattern with peaks at 4.7, 13.5, 17.7, 18.3, and 23.7±0.2 degrees two theta; a powder XRD pattern with peaks at about 4.7, 13.5, and 15.5±0.2 degrees two theta and at least another two peaks selected from the following list: 14.0, 14.4, 18.3, 19.2, 19.5 and 23.7±0.2 degrees two theta; and a powder XRD pattern with peaks at about 13.5, 19.2, and 19.5±0.2 degrees two theta and at least another two peaks selected from the following list: 4.7, 14.0, 15.1, 15.5, 18.3, and 18.7±0.2 degrees two theta; a powder XRD pattern with peaks at about 13.5, 15.5, 19.2, 23.7, and 24.4±0.2 degrees two theta; and a powder XRD pattern with peaks at about 4.65, 13.46, 17.63, 18.30, and 23.66±0.10 degrees two theta, processes for preparing said Sitagliptin crystalline form, and pharmaceutical compositions thereof, are provided.

    Abstract translation: 磷酸西他列汀,其特征在于选自以下的数据:粉末XRD图谱,其峰为4.7,13.5,17.7,18.3和23.7±0.2度2θ; 在约4.7,13.5和15.5±0.2度2θ处具有峰的粉末XRD图案和至少另外两个选自以下列表的峰:14.0,14.4,18.3,19.2,19.5和23.7±0.2度2θ; 和具有在约13.5,19.2和19.5±0.2度2θ处以及从下列列表中选择的至少另外两个峰的峰的粉末XRD图:4.7,14.0,15.1,15.5,18.3和18.7±0.2度2θ; 在约13.5,15.5,19.2,23.7和24.4±0.2度2θ处具有峰的粉末XRD图案; 并且提供了在约4.65,13.46,17.63,18.30和23.66±0.10度2θ处具有峰的粉末XRD图案,制备所述西格列汀结晶形式的方法及其药物组合物。

Patent Agency Ranking